Home LiteratureArticle Details
PMID: 19433685 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA

Abstract

PURPOSE Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern 4. These studies have influenced clinical practice, but it is unclear if rates of PCa mortality differ for 3 + 4 and 4 + 3 tumors. Using PCa mortality as the primary end point, we compared outcomes in Gleason 3 + 4 and 4 + 3 cancers, and the predictive ability of GS from a standardized review versus original scoring. PATIENTS AND METHODS Three study pathologists conducted a blinded standardized review of 693 prostatectomy and 119 biopsy specimens to assign primary and secondary Gleason patterns. Tumor specimens were from PCa patients diagnosed between 1984 and 2004 from the Physicians' Health Study and Health Professionals Follow-Up Study. Lethal PCa (n = 53) was defined as development of bony metastases or PCa death. Hazard ratios (HR) were estimated according to original GS and standardized GS. We compared the discrimination of standardized and original grading with C-statistics from models of 10-year survival. Results For prostatectomy specimens, 4 + 3 cancers were associated with a three-fold increase in lethal PCa compared with 3 + 4 cancers (95% CI, 1.1 to 8.6). The discrimination of models of standardized scores from prostatectomy (C-statistic, 0.86) and biopsy (C-statistic, 0.85) were improved compared to models of original scores (prostatectomy C-statistic, 0.82; biopsy C-statistic, 0.72). CONCLUSION Ignoring the predominance of Gleason pattern 4 in GS 7 cancers may conceal important prognostic information. A standardized review of GS can improve prediction of PCa survival.

MeSH Terms
Biopsy Follow-Up Studies Humans Male Neoplasm Invasiveness Neoplasm Staging Postoperative Complications Prognosis Prostatectomy Prostatic Neoplasms/drug therapy,mortality,pathology,surgery Time Factors Treatment Outcome
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Stark Jennifer R
ScD, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA. [email protected].
Perner Sven
Stampfer Meir J
Sinnott Jennifer A
Finn Stephen
Eisenstein Anna S
Ma Jing
Fiorentino Michelangelo
Kurth Tobias
Loda Massimo
Giovannucci Edward L
Rubin Mark A
Mucci Lorelei A
References (32)
32 references, click to expand
  1. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
    BJU Int. 2004 Jul;94(1):42-6 PMID: 15217428
  2. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
    J Urol. 2001 Apr;165(4):1146-51 PMID: 11257657
  3. The Gleason score shift: score four and seven years ago.
    Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1241-7 PMID: 12873667
  4. Nomograms for prostate cancer.
    BJU Int. 2006 Jul;98(1):39-46 PMID: 16831140
  5. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
    JAMA. 1998 Sep 16;280(11):969-74 PMID: 9749478
  6. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer.
    Urology. 2007 Oct;70(4):706-10 PMID: 17707892
  7. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.
    Ann Epidemiol. 2000 Feb;10(2):125-34 PMID: 10691066
  8. Biological determinants of cancer progression in men with prostate cancer.
    JAMA. 1999 Apr 21;281(15):1395-400 PMID: 10217055
  9. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
    Cancer. 2002 Apr 15;94(8):2282-7 PMID: 12001128
  10. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    J Urol. 2002 Jun;167(6):2440-2 PMID: 11992053
  11. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
    Urology. 2000 Nov 1;56(5):823-7 PMID: 11068310
  12. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    JAMA. 1997 May 14;277(18):1445-51 PMID: 9145716
  13. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.
    J Urol. 2006 Apr;175(4):1337-40 PMID: 16515993
  14. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
    Cancer. 2006 Jun 15;106(12):2630-5 PMID: 16703592
  15. The case for modifying the Gleason grading system.
    BJU Int. 2007 Oct;100(4):725-6 PMID: 17559561
  16. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
    J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54 PMID: 18695132
  17. Overdiagnosis of prostatic adenocarcinoma.
    Semin Urol Oncol. 1999 Nov;17(4):199-205 PMID: 10632121
  18. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
    Urology. 2003 Feb;61(2):365-9 PMID: 12597949
  19. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83 PMID: 13130113
  20. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    J Urol. 2001 Nov;166(5):1692-7 PMID: 11586204
  21. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma.
    Cancer. 2003 Dec 15;98(12):2560-5 PMID: 14669274
  22. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
    BJU Int. 2007 Dec;100(6):1240-4 PMID: 17979924
  23. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
    Urol Clin North Am. 2002 Feb;29(1):173-81 PMID: 12109343
  24. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.
    Urology. 2007 Aug;70(2):277-82 PMID: 17826489
  25. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta").
    Urology. 2005 Nov;66(5 Suppl):83-94 PMID: 16194712
  26. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.
    N Engl J Med. 1996 May 2;334(18):1145-9 PMID: 8602179
  27. Natural history of progression after PSA elevation following radical prostatectomy.
    JAMA. 1999 May 5;281(17):1591-7 PMID: 10235151
  28. Final report on the aspirin component of the ongoing Physicians' Health Study.
    N Engl J Med. 1989 Jul 20;321(3):129-35 PMID: 2664509
  29. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made.
    Am J Surg Pathol. 2000 Apr;24(4):477-8 PMID: 10757394
  30. Prostate cancer and the Will Rogers phenomenon.
    J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53 PMID: 16145045
  31. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.
    J Urol. 1974 Jan;111(1):58-64 PMID: 4813554
  32. Histologic grading of prostate cancer: a perspective.
    Hum Pathol. 1992 Mar;23(3):273-9 PMID: 1555838
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
Published
2009-07-20
Epub
2009-00-11
Pages
3459-64
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC2717753
Subset
IM
Grants
NHLBI NIH HHS · HL-34595 · United States
NHLBI NIH HHS · HL-26490 · United States
NHLBI NIH HHS · R01 HL034595 · United States
NCI NIH HHS · CA097193 · United States
NCI NIH HHS · T32CA009001-32 · United States
NCI NIH HHS · R01 CA058684 · United States
NCI NIH HHS · 5R01CA042182-20 · United States
NCI NIH HHS · T32 CA009001 · United States
NCI NIH HHS · 5R01CA058684-13 · United States
NCI NIH HHS · R01 CA040360 · United States
NCI NIH HHS · R01 CA034944 · United States
NCI NIH HHS · R01 CA042182 · United States
NHLBI NIH HHS · R01 HL026490 · United States
NCI NIH HHS · R01 CA097193 · United States
NCI NIH HHS · CA40360 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]